pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Obesity · news · pharmadog
← back to Obesity
News mentioning Obesity
737
stories
Sep 22, 26
2026 IPO blitz continues with 4 new biotech filings
biospace
Sep 22, 26
Novo’s workforce reduction climbs to 13,000 to fuel R&D work
biospace
Sep 22, 26
Roche’s Carmot asset normalizes blood sugar, cuts weight in Phase 2 diabetes trial
biospace
Sep 22, 26
STAT+: Pharmalittle: We’re reading about pharma seeking to protect China deals, a Roche obesity drug, and more
stat
Sep 22, 26
Siemens Healthineers and Novo team up on fatty liver disease awareness, testing
fiercebiotech
Sep 22, 26
Roche’s GLP-1/GIP drug hits in phase 2 diabetes trial, fueling best-in-disease hopes
fiercebiotech
Sep 21, 26
Novo talks up drug launches in effort to win back investors
biopharma dive
Sep 21, 26
Novo offers low-dose CagriSema data as approval decision looms
endpoints
Sep 21, 26
Novo’s plan to hit $23B in revenue by 2035 leaves investors wanting
biospace
Sep 21, 26
STAT+: Pharmalittle: We’re reading about Novo plans to expand its pipeline, early Alkermes ADHD data, and more
stat
Sep 21, 26
Novo buys three early-stage obesity assets from Kallyope as investor pressure mounts
biospace
Sep 21, 26
STAT+: Alkermes’ orexin agonist shows potential to treat ADHD in early-stage trial
stat
Sep 21, 26
Novo struggles to appease restive investors with consumer plans, blockbuster ambitions
fiercebiotech
Sep 21, 26
STAT+: With new strategy, Novo outlines plans for obesity, direct-to-consumer work
stat
Sep 21, 26
Are healthcare systems really ready for GLP-1s?
biopharma dive
Sep 18, 26
China plans to transform biotech sector into $522B powerhouse by 2030
biospace
Sep 18, 26
Artelo’s ex-AstraZeneca cannabinoid agonist holds its own against GLP-1 drug semaglutide in obese mice
fiercebiotech
Sep 18, 26
Refreshed Novo corrals 3 new early-stage obesity drugs from Kallyope
fiercebiotech
Sep 17, 26
STAT+: FDA approves a new gene therapy for Sanfilippo syndrome, an ultra-rare disease
stat
Sep 17, 26
Definium’s new psychedelics data, and a reprieve for international scientists
stat
Sep 17, 26
Novo partners with Orbis, deepening investment in oral peptide drugs
biopharma dive
Sep 17, 26
Novo notches up to $1.4B pact with Orbis to develop oral macrocycle cardiometabolic drugs
biospace
Sep 17, 26
STAT+: New startup to test psychedelic-like drug against Parkinson’s symptom
stat
Sep 17, 26
Roche bets up to $1B to advance next-gen bispecifics with Dualitas
biospace
Sep 16, 26
'Still a bull': Novo's CEO on honoring heritage and planning for the future amid corporate rebrand
fiercebiotech
Sep 16, 26
STAT+: Sen. Warren demands to see Trump drug-pricing pharma contracts, accuses RFK Jr. of hiding them
stat
Sep 15, 26
FDA clears first generic radioligand drug; Sionna turns to layoffs
biopharma dive
Sep 15, 26
A fourth measles death is reported in Pennsylvania
stat
Sep 15, 26
STAT+: RFK Jr. returns to his roots
stat
Sep 15, 26
STAT+: Medicare to expand its pilot that pays for technology to manage chronic diseases
stat
← prev
page 10 of 25
next →